Key statistics
As of last trade Resmed Inc (RME:HAN) traded at 216.50, -5.33% below its 52-week high of 228.70, set on Sep 12, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 216.50 |
---|---|
High | 216.50 |
Low | 216.50 |
Bid | 216.00 |
Offer | 218.10 |
Previous close | 215.80 |
Average volume | 0.00 |
---|---|
Shares outstanding | 146.93m |
Free float | 145.76m |
P/E (TTM) | 35.11 |
Market cap | 35.70bn USD |
EPS (TTM) | 6.92 USD |
Annual div (ADY) | 1.93 EUR |
---|---|
Annual div yield (ADY) | 0.90% |
Div ex-date | Aug 15 2024 |
Div pay-date | Sep 19 2024 |
Data delayed at least 15 minutes, as of Sep 20 2024 07:01 BST.
More ▼
Announcements
- ResMed to Host Its 2024 Investor Day on September 30, 2024, at the New York Stock Exchange
- Vaping Expected to Increase COPD Health and Economic Burden by 2050
- ResMed Announces Participation in the Morgan Stanley 22nd Annual Global Healthcare Conference
- ResMed Expands its Board of Directors and Appoints Healthcare Executive and Seasoned Finance Leader Christopher DelOrefice to its Board
- ResMed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2024
- ResMed to Report Fourth Quarter Fiscal 2024 Earnings on August 1, 2024
- PAP Therapy Reduces Hospitalizations by 31% and ER Visits by 23% for People with Obstructive Sleep Apnea and Comorbid Insomnia
- Developed in Collaboration with Leading Scientists, New ResMed-Supported Research at ATS 2024 Provides Evidence of the Effectiveness and Critical Role of Positive Airway Pressure Therapy
- ATS 2024: New ResMed-Supported Research Shows Increasing Prevalence of Obstructive Sleep Apnea and Critical Role of PAP Therapy
- ResMed Announces Participation in the RBCCM Global Healthcare Conference
More ▼